
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/473343/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Surfactant free synthesis of cationic nano-vesicles: A safe triple drug loaded vehicle for the topical treatment of cutaneous leishmaniasis. Nanomedicine: Nanotechnology, Biology, and Medicine, 2022, 40, 102490.	1.7	9
2	Leishmania Major Centrin Gene-Deleted Parasites Generate Skin Resident Memory T-Cell Immune Response Analogous to Leishmanization. Frontiers in Immunology, 2022, 13, 864031.	2.2	7
3	Centrin-deficient Leishmania mexicana confers protection against New World cutaneous leishmaniasis. Npj Vaccines, 2022, 7, 32.	2.9	19
4	The History of Live Attenuated Centrin Gene-Deleted Leishmania Vaccine Candidates. Pathogens, 2022, 11, 431.	1.2	13
5	Understanding the immune responses involved in mediating protection or immunopathology during leishmaniasis. Biochemical Society Transactions, 2021, 49, 297-311.	1.6	13
6	Effect of Short-Term Tacrolimus Exposure on Rat Liver: An Insight into Serum Antioxidant Status, Liver Lipid Peroxidation, and Inflammation. Mediators of Inflammation, 2021, 2021, 1-12.	1.4	9
7	MicroRNA155 Plays a Critical Role in the Pathogenesis of Cutaneous Leishmania major Infection by Promoting a Th2 Response and Attenuating Dendritic Cell Activity. American Journal of Pathology, 2021, 191, 809-816.	1.9	8
8	MicroRNA-21 Deficiency Promotes the Early Th1 Immune Response and Resistance toward Visceral Leishmaniasis. Journal of Immunology, 2021, 207, 1322-1332.	0.4	17
9	Pentalinonsterol, a Phytosterol from Pentalinon andrieuxii, is Immunomodulatory through Phospholipase A2 in Macrophages toward its Antileishmanial Action. Cell Biochemistry and Biophysics, 2021, , 1.	0.9	2
10	Molecular characterization and genetic diversity of cutaneous leishmaniasis from North Eastern Pakistan. Acta Tropica, 2021, 221, 105964.	0.9	0
11	From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection. Expert Review of Vaccines, 2021, 20, 1431-1446.	2.0	27
12	Determinants of Innate Immunity in Visceral Leishmaniasis and Their Implication in Vaccine Development. Frontiers in Immunology, 2021, 12, 748325.	2.2	24
13	STAT1-Dependent Recruitment of Ly6ChiCCR2+ Inflammatory Monocytes and M2 Macrophages in a Helminth Infection. Pathogens, 2021, 10, 1287.	1.2	3
14	Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes. International Journal of Pharmaceutics, 2020, 573, 118900.	2.6	25
15	Development and evaluation of novel miltefosine-polyphenol co-loaded second generation nano-transfersomes for the topical treatment of cutaneous leishmaniasis. Expert Opinion on Drug Delivery, 2020, 17, 97-110.	2.4	34
16	Integrative genomic, proteomic and phenotypic studies of Leishmania donovani strains revealed genetic features associated with virulence and antimony-resistance. Parasites and Vectors, 2020, 13, 510.	1.0	10
17	A listeriolysin O subunit vaccine is protective against Listeria monocytogenes. Vaccine, 2020, 38, 5803-5813.	1.7	11
18	Nano-elastic liposomes as multidrug carrier of sodium stibogluconate and ketoconazole: A potential new approach for the topical treatment of cutaneous Leishmaniasis. European Journal of Pharmaceutical Sciences, 2020, 145, 105256.	1.9	25

#	Article	IF	CITATIONS
19	A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing. Nature Communications, 2020, 11, 3461.	5.8	72
20	Macrophage migration inhibitory factor inhibition as a novel therapeutic approach against triple-negative breast cancer. Cell Death and Disease, 2020, 11, 774.	2.7	39
21	Oral delivery and enhanced efficacy of antimonal drug through macrophage-guided multifunctional nanocargoes against visceral Leishmaniasis. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 152, 307-317.	2.0	9
22	Cutaneous Leishmaniasis due to Three Leishmania Species Among Syrian Refugees in Sanliurfa, Southeastern Turkey. Acta Parasitologica, 2020, 65, 936-948.	0.4	2
23	Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells. British Journal of Cancer, 2020, 122, 1005-1013.	2.9	52
24	Risk of aortic dissection in patients with ascending aorta aneurysm: a new biological, morphological, and biomechanical network behind the aortic diameter. Vessel Plus, 2020, 4, 28.	0.4	7
25	Host-directed therapies for parasitic diseases. Future Medicinal Chemistry, 2019, 11, 1999-2018.	1.1	13
26	Evaluation of synergy between host and pathogen-directed therapies against intracellular Leishmania donovani. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 10, 125-132.	1.4	12
27	Mannosylated thiolated paromomycin-loaded PLGA nanoparticles for the oral therapy of visceral leishmaniasis. Nanomedicine, 2019, 14, 387-406.	1.7	47
28	MicroRNA 155 Contributes to Host Immunity against Leishmania donovani but Is Not Essential for Resolution of Infection. Infection and Immunity, 2019, 87, .	1.0	14
29	<i>Taenia crassiceps</i> -Excreted/Secreted Products Induce a Defined MicroRNA Profile that Modulates Inflammatory Properties of Macrophages. Journal of Immunology Research, 2019, 2019, 1-24.	0.9	9
30	Elevated Expression of Macrophage Migration Inhibitory Factor Promotes Inflammatory Bone Resorption Induced in a Mouse Model of Periradicular Periodontitis. Journal of Immunology, 2019, 202, 2035-2043.	0.4	19
31	Lymphocytes influence Leishmania major pathogenesis in a strain-dependent manner. PLoS Neglected Tropical Diseases, 2019, 13, e0007865.	1.3	10
32	The Potent ITK/BTK Inhibitor Ibrutinib Is Effective for the Treatment of Experimental Visceral Leishmaniasis Caused by Leishmania donovani. Journal of Infectious Diseases, 2019, 219, 599-608.	1.9	24
33	MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages. JCI Insight, 2019, 4, .	2.3	33
34	Macrophage migration inhibitory factor (MIF):A novel therapeutic target against aggressive breast cancer. FASEB Journal, 2019, 33, 674.3.	0.2	0
35	Lymphocytes influence Leishmania major pathogenesis in a strain-dependent manner. , 2019, 13, e0007865.		0
36	Lymphocytes influence Leishmania major pathogenesis in a strain-dependent manner. , 2019, 13, e0007865.		0

#	Article	IF	CITATIONS
37	Lymphocytes influence Leishmania major pathogenesis in a strain-dependent manner. , 2019, 13, e0007865.		Ο
38	Lymphocytes influence Leishmania major pathogenesis in a strain-dependent manner. , 2019, 13, e0007865.		0
39	Lymphocytes influence Leishmania major pathogenesis in a strain-dependent manner. , 2019, 13, e0007865.		О
40	Design of mannosylated oral amphotericin B nanoformulation: efficacy and safety in visceral leishmaniasis. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 521-531.	1.9	28
41	Fibroblast-derived CXCL12 promotes breast cancer metastasis by facilitating tumor cell intravasation. Oncogene, 2018, 37, 4428-4442.	2.6	95
42	Host-Directed Drug Therapies for Neglected Tropical Diseases Caused by Protozoan Parasites. Frontiers in Microbiology, 2018, 9, 2655.	1.5	45
43	Deficiency in STAT1 Signaling Predisposes Gut Inflammation and Prompts Colorectal Cancer Development. Cancers, 2018, 10, 341.	1.7	21
44	Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. OncoImmunology, 2018, 7, e1486948.	2.1	41
45	Inhibitors of elastase stimulate murine B lymphocyte differentiation into IgG―and IgAâ€producing cells. European Journal of Immunology, 2018, 48, 1295-1301.	1.6	7
46	Intestinal Epithelial Cells Regulate Gut Eotaxin Responses and Severity of Allergy. Frontiers in Immunology, 2018, 9, 1692.	2.2	14
47	Helminth-induced Ly6Chi monocyte-derived alternatively activated macrophages suppress experimental autoimmune encephalomyelitis. Scientific Reports, 2017, 7, 40814.	1.6	28
48	Topical treatment with nanoliposomal Amphotericin B reduces early lesion growth but fails to induce cure in an experimental model of cutaneous leishmaniasis caused by Leishmania mexicana. Acta Tropica, 2017, 173, 102-108.	0.9	20
49	Ly6Chi inflammatory monocytes promote susceptibility to Leishmania donovani infection. Scientific Reports, 2017, 7, 14693.	1.6	62
50	Interleukinâ€⊋7 signalling induces stem cell antigenâ€1 expression in T lymphocytes <i>inÂvivo</i> . Immunology, 2017, 152, 638-647.	2.0	8
51	STAT1 gene deficient mice develop accelerated breast cancer growth and metastasis which is reduced by IL-17 blockade. Oncolmmunology, 2017, 6, e1361088.	2.1	30
52	Pentalinonsterol, a Constituent of Pentalinon andrieuxii, Possesses Potent Immunomodulatory Activity and Primes T Cell Immune Responses. Journal of Natural Products, 2017, 80, 2515-2523.	1.5	10
53	Efficacy, Safety and Cost-Effectiveness of Thermotherapy in the Treatment of Leishmania donovani–Induced Cutaneous Leishmaniasis: A Randomized Controlled Clinical Trial. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1120-1126.	0.6	22
54	MIF Promotes Classical Activation and Conversion of Inflammatory Ly6ChighMonocytes into TipDCs during Murine Toxoplasmosis. Mediators of Inflammation, 2016, 2016, 1-18.	1.4	19

#	Article	IF	CITATIONS
55	Pediatric Cutaneous Leishmaniasis in an Endemic Region in Turkey: A Retrospective Analysis of 8786 Cases during 1998-2014. PLoS Neglected Tropical Diseases, 2016, 10, e0004835.	1.3	20
56	Deletion of macrophage migration inhibitory factor inhibits murine oral carcinogenesis: Potential role for chronic proâ€inflammatory immune mediators. International Journal of Cancer, 2016, 139, 1379-1390.	2.3	32
5 <b>7</b>	Treatment Options for Leishmaniasis. Current Clinical Microbiology Reports, 2016, 3, 198-203.	1.8	Ο
58	A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. Cancer Research, 2016, 76, 3838-3850.	0.4	212
59	Transgenic T cell-specific expression of CXCR3 enhances splenic and hepatic T cell accumulation but does not affect the outcome of visceral leishmaniasis. Cellular Immunology, 2016, 309, 61-68.	1.4	1
60	STAT4 is required for the generation of Th1 and Th2, but not Th17 immune responses during monophosphoryl lipid A adjuvant activity. International Immunology, 2016, 28, 565-570.	1.8	8
61	Differential gene expression pattern in biopsies with renal allograft pyelonephritis and allograft rejection. Clinical Transplantation, 2016, 30, 1115-1133.	0.8	11
62	A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells. Oncolmmunology, 2016, 5, e1151592.	2.1	17
63	Immune response to infection by Leishmania: A mathematical model. Mathematical Biosciences, 2016, 276, 28-43.	0.9	24
64	Antileishmanial and Cytotoxic Activity of Some Highly Oxidized Abietane Diterpenoids from the Bald Cypress, <i>Taxodium distichum</i> . Journal of Natural Products, 2016, 79, 598-606.	1.5	33
65	Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells. Oncolmmunology, 2016, 5, e1057385.	2.1	31
66	ILâ€17A promotes susceptibility during experimental visceral leishmaniasis caused by <i>Leishmania donovani</i> . FASEB Journal, 2016, 30, 1135-1143.	0.2	58
67	Meglumine antimoniate is more effective than sodium stibogluconate in the treatment of cutaneous leishmaniasis. Journal of Dermatological Treatment, 2016, 27, 83-87.	1.1	20
68	Immunology and Cell Biology of Parasitic Diseases 2014. BioMed Research International, 2015, 2015, 1-3.	0.9	0
69	Extraintestinal Helminth Infection Limits Pathology and Proinflammatory Cytokine Expression during DSS-Induced Ulcerative Colitis: A Role for Alternatively Activated Macrophages and Prostaglandins. BioMed Research International, 2015, 2015, 1-17.	0.9	30
70	Transgenic Expression of CXCR3 on T Cells Enhances Susceptibility to Cutaneous Leishmania major Infection by Inhibiting Monocyte Maturation and Promoting a Th2 Response. Infection and Immunity, 2015, 83, 67-76.	1.0	9
71	Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel antiâ€ŧumor mechanisms of Cannabidiol in breast cancer. Molecular Oncology, 2015, 9, 906-919.	2.1	170
72	Northalrugosidine Is a Bisbenzyltetrahydroisoquinoline Alkaloid from <i>Thalictrum alpinum</i> with in Vivo Antileishmanial Activity. Journal of Natural Products, 2015, 78, 552-556.	1.5	21

#	Article	IF	CITATIONS
73	A Comparison of Demographic and Clinical Characteristics of Syrian and Turkish Patients with Cutaneous Leishmaniasis. American Journal of Tropical Medicine and Hygiene, 2015, 93, 559-563.	0.6	9
74	Uncovering Leishmania–macrophage interplay using imaging flow cytometry. Journal of Immunological Methods, 2015, 423, 93-98.	0.6	27
75	Immunomodulatory and Antileishmanial Activity of Phenylpropanoid Dimers Isolated from <i>Nectandra leucantha</i> . Journal of Natural Products, 2015, 78, 653-657.	1.5	58
76	A Novel Sterol Isolated from a Plant Used by Mayan Traditional Healers Is Effective in Treatment of Visceral Leishmaniasis Caused by <i>Leishmania donovani</i> . ACS Infectious Diseases, 2015, 1, 497-506.	1.8	18
77	CXCR3 expression defines a novel subset of innate CD8 + T cells that enhance immunity against bacterial infection and cancer upon stimulation with ILâ€15. FASEB Journal, 2015, 29, 1019-1028.	0.2	29
78	Ox40L–Ox40 pathway plays distinct roles in regulating Th2 responses but does not determine outcome of cutaneous leishmaniasis caused by Leishmania mexicana and Leishmania major. Experimental Parasitology, 2015, 148, 49-55.	0.5	7
79	Challenges for management of post kala-azar dermal leishmaniasis and future directions. Research and Reports in Tropical Medicine, 2014, 5, 105.	2.8	6
80	MIF Antagonist (CPSI-1306) Protects against UVB-Induced Squamous Cell Carcinoma. Molecular Cancer Research, 2014, 12, 1292-1302.	1.5	16
81	Characterization of Cross-Protection by Genetically Modified Live-Attenuated <i>Leishmania donovani</i> Parasites against <i>Leishmania mexicana</i> . Journal of Immunology, 2014, 193, 3513-3527.	0.4	56
82	Pediatric Cutaneous Leishmaniasis in an Endemic Region in India. American Journal of Tropical Medicine and Hygiene, 2014, 91, 901-904.	0.6	27
83	<i>Pentalinon andrieuxii</i> Root Extract is Effective in the Topical Treatment of Cutaneous Leishmaniasis Caused by <i>Leishmania mexicana</i> . Phytotherapy Research, 2014, 28, 909-916.	2.8	24
84	Bioactive indole alkaloids isolated from Alstonia angustifolia. Phytochemistry Letters, 2014, 10, liv-lix.	0.6	35
85	Role of Macrophage Migration Inhibitory Factor (MIF) in Parasitic Diseases. , 2012, , 215-230.		Ο
86	Sterols with antileishmanial activity isolated from the roots of Pentalinon andrieuxii. Phytochemistry, 2012, 82, 128-135.	1.4	49
87	Leishmanicidal activity of racemic ± 8-[(4-Amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline. Natural Product Communications, 2010, 5, 1934578X1000500.	0.2	5
88	Cytokines and Their STATs in Cutaneous and Visceral Leishmaniasis. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-6.	3.0	52
89	MIF in Parasitic and Helminthic Infections. , 2007, , 133-151.		2
90	Leishmanicidal Activity of Artemisinin, Deoxoartemisinin, Artemether and Arteether. Natural Product Communications, 2007, 2, 1934578X0700200.	0.2	3

#	Article	IF	CITATIONS
91	Signals through CD40 Play a Critical Role in the Pathophysiology of Schistosoma Mansoni Egg Antigen–Induced Allergic Rhinitis in Mice. American Journal of Rhinology & Allergy, 2006, 20, 165-169.	2.3	10
92	Leishmania inhibits STAT1-mediated IFN-l <sup>3</sup> signaling in macrophages: increased tyrosine phosphorylation of dominant negative STAT1l² by Leishmania mexicana. International Journal for Parasitology, 2005, 35, 75-82.	1.3	42
93	Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice. International Immunology, 2005, 17, 1347-1357.	1.8	68
94	Susceptibility toLeishmania mexicanainfection is due to the inability to produce ILâ€12 rather than lack of ILâ€12 responsiveness. Immunology and Cell Biology, 2001, 79, 320-322.	1.0	27
95	SAP controls T cell responses to virus and terminal differentiation of TH2 cells. Nature Immunology, 2001, 2, 410-414.	7.0	219
96	Development of chronic colitis is dependent on the cytokine MIF. Nature Immunology, 2001, 2, 1061-1066.	7.0	288
97	Migration-Inhibitory Factor Gene-Deficient Mice Are Susceptible to Cutaneous Leishmania major Infection. Infection and Immunity, 2001, 69, 906-911.	1.0	117
98	Interleukin-4-deficient BALB/c mice develop an enhanced Th1-like response but control cardiac inflammation followingBorrelia burgdorferiinfection. FEMS Microbiology Letters, 2000, 183, 319-325.	0.7	13
99	Targeted Disruption of Migration Inhibitory Factor Gene Reveals Its Critical Role in Sepsis. Journal of Experimental Medicine, 1999, 189, 341-346.	4.2	510
100	STAT-4 mediated IL-12 signaling pathway is critical for the development of protective immunity in cutaneous leishmaniasis. European Journal of Immunology, 1999, 29, 2524-2529.	1.6	64
101	The PACAP-type I receptor agonist maxadilan from sand fly saliva protects mice against lethal endotoxemia by a mechanism partially dependent on IL-10. European Journal of Immunology, 1998, 28,	1.6	45